Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

v3.21.2
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2021
Stockholders' Equity Note [Abstract]  
Schedule of the changes in outstanding warrants
    Number
of
Options
    Weighted
Average
Exercise
Price
Per
Share
    Weighted
Average
Remaining
Contractual
Term
(Years)
    Aggregate
Intrinsic
Value
 
Outstanding and expected to vest at December 31, 2020     3,905,737     $ 24.32       8.40     $ 48,952,339  
Granted     1,515,000     $ 33.46       9.28     $  
Exercised     (160,556 )   $ 3.56      
    $
 
Forfeited     (216,250 )   $ 39.61      
    $
 
Outstanding  at September 30, 2021     5,043,931     $ 27.07       8.18     $ 33,664,009  
Options exercisable at September 30, 2021     2,079,396     $ 22.59       7.54     $ 21,827,709  

 

Schedule of the changes in outstanding warrants
    Number of
Shares
    Weighted
Average
Exercise
Price Per
Share
 
Outstanding and vested at December 31, 2020     2,670,633     $ 9.11  
Granted     930,000     $ 32.21  
Exercised     (356,385 )   $ 5.94  
Outstanding at September 30, 2021     3,244,248     $ 16.08  
Warrants Vested at September 30, 2021     2,829,873     $ 8.13  

Schedule of stock-based compensation expense
    Nine
Months
Ended
September 30,
2021
    Nine
Months
Ended
September 30,
2020
 
Research and development   $ 14,341,700     $ 4,635,300  
General and administrative     18,033,500       12,951,200  
Total   $ 32,375,200     $ 17,586,500